CD274 and neoplasm: Compared with systemic treatments, local administration of anti-PD-L1 antibodies targeting TDLNs elicited superior anti-tumor therapeutic effects, and PD-L1+ conventional dendritic cells (DCs), rather than other myeloid cells, were the primary targets of PD-L1 inhibition (47–49).